MGX
BEARISH
$1.4
Live
Metagenomi Therapeutics, Inc. · NASDAQ
Target $9.33
(+566.7%)
$1.25
52W Range
$3.95
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$52.67M
P/E
N/A
ROE
-44.7%
Profit margin
N/A
Debt/Equity
0.26
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
MGX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company suffers from a catastrophic negative gross margin (-274.58%) and a significant decline in year-over-year revenue (-59.30%), suggesting a failing or highly inefficient business model. While the current ratio of 7.22 provides a temporary liquidity cushion, the combination of bearish insider selling by the CEO and CFO and a 0/100 technical trend suggests a lack of confidence in near-term recovery. Despite a high analyst target price of $9.33, the deterministic data points to a high-risk speculative asset in a downward spiral.
Key Strengths
Strong short-term liquidity (Current Ratio: 7.22)
Low leverage (Debt/Equity: 0.26)
Trading significantly below book value (P/B: 0.33)
High optimistic analyst price target ($9.33)
Low total debt relative to equity
Key Risks
Critical fundamental weakness (Piotroski F-Score: 0/9)
Negative gross margins indicating unsustainable cost structure
Severe revenue contraction (-59.30% YoY)
Bearish insider activity with C-suite selling
Extreme price depreciation (-86.4% over 5 years)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
11
Weak
30
10
10
5
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski 0/9, Negative Gross Margins, Revenue Collapse, Insider Selling
Confidence
90%
Value
30/100
Trades at a deep discount to book value, but lacks earnings to support a Graham Number.
Positives
- Low Price-to-Book (0.33)
Watchpoints
- No earnings for P/E calculation
- Negative forward P/E
Future
10/100
Growth metrics are sharply negative, contradicting analyst optimism.
Positives
- High analyst target price
Watchpoints
- Revenue growth -59.30%
- Q/Q revenue growth -59.32%
Past
10/100
Long-term and medium-term price performance is overwhelmingly bearish.
Positives
No standout positives identified.
Watchpoints
- 5Y Change -86.4%
- 6M Change -50.9%
Health
5/100
Liquidity is the only positive; operational health is non-existent.
Positives
- High Current Ratio
Watchpoints
- Piotroski F-Score 0/9
- Operating Margin -623.04%
Dividend
0/100
Non-dividend paying growth/biotech entity.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.4
Analyst Target
$9.33
Upside/Downside
+566.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MGX and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MGX
Metagenomi Therapeutics, Inc.
Primary
|
-86.4% | -86.4% | -7.9% | -50.9% | -4.1% | +2.9% |
|
HYFT
MindWalk Holdings Corp.
Peer
|
-91.3% | -62.5% | +166.8% | -40.9% | -16.4% | -6.1% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
|
DCGO
DocGo Inc.
Peer
|
-94.3% | -93.1% | -77.6% | -55.1% | -15.2% | -9.4% |
|
ELUT
Elutia Inc.
Peer
|
-91.4% | -20.8% | -53.7% | +28.2% | -2.6% | +4.6% |
MGX
Metagenomi Therapeutics, Inc.
Primary
5Y
-86.4%
3Y
-86.4%
1Y
-7.9%
6M
-50.9%
1M
-4.1%
1W
+2.9%
HYF
MindWalk Holdings Corp.
Peer
5Y
-91.3%
3Y
-62.5%
1Y
+166.8%
6M
-40.9%
1M
-16.4%
1W
-6.1%
BTM
biote Corp.
Peer
5Y
-85.2%
3Y
-74.7%
1Y
-54.1%
6M
-47.5%
1M
-16.8%
1W
+10.4%
DCG
DocGo Inc.
Peer
5Y
-94.3%
3Y
-93.1%
1Y
-77.6%
6M
-55.1%
1M
-15.2%
1W
-9.4%
ELU
Elutia Inc.
Peer
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.84
PEG Ratio
N/A
P/B Ratio
0.33
P/S Ratio
2.09
EV/Revenue
-2.68
EV/EBITDA
0.74
Market Cap
$52.67M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-623.04%
Gross Margin
-274.58%
ROE
-44.66%
ROA
-21.99%
Growth
Revenue and earnings growth rates
Revenue Growth
-59.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-59.32%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.26
Low debt
Current Ratio
7.22
Strong
Quick Ratio
7.08
Excellent
Cash/Share
$4.27
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-623.0%
Net Margin
-576.0%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.39x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-05
$-0.6
-2.6% surprise
2025-11-11
$-0.55
-3.1% surprise
2025-08-13
$N/A
2025-08-12
$-0.54
+12.0% surprise
Healthcare Sector Comparison
Comparing MGX against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-44.66%
This Stock
vs
-86.0%
Sector Avg
-48.1%
(Below Avg)
Debt to Equity
0.26
This Stock
vs
3.51
Sector Avg
-92.7%
(Less Debt)
Revenue Growth
-59.3%
This Stock
vs
90.15%
Sector Avg
-165.8%
(Slower)
Current Ratio
7.22
This Stock
vs
3.67
Sector Avg
+96.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MGX
Metagenomi Therapeutics, Inc.
|
BEARISH | $52.67M | - | -44.7% | -% | $1.4 | |
|
HYFT
MindWalk Holdings Corp.
|
BEARISH | $49.98M | - | -58.8% | -43.6% | $1.07 | Compare |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
|
DCGO
DocGo Inc.
|
BEARISH | $56.28M | - | -89.0% | -56.6% | $0.57 | Compare |
|
ELUT
Elutia Inc.
|
BULLISH | $48.77M | - | -% | 434.2% | $1.14 | Compare |
MGX
Metagenomi...
BEARISH
Mkt Cap
$53M
P/E
-
ROE
-44.7%
Price
$1.4
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | WAPNICK PAMELA M. | Chief Financial Officer | Stock Award | 24,000 | - |
| 2026-04-01 | WEIN MATTHEW | General Counsel | Stock Award | 11,000 | - |
| 2026-04-01 | IRISH JIAN | Chief Executive Officer | Stock Award | 46,000 | - |
| 2026-03-05 | WAPNICK PAMELA M. | Chief Financial Officer | Sale | 1,581 | $2,530 |
| 2026-03-05 | WEIN MATTHEW | General Counsel | Sale | 482 | $771 |
| 2026-03-05 | IRISH JIAN | Chief Executive Officer | Sale | 1,607 | $2,571 |
| 2025-12-05 | WAPNICK PAMELA M. | Chief Financial Officer | Sale | 1,576 | $2,793 |
| 2025-12-05 | THOMAS BRIAN C | Director | Sale | 3,830 | $6,786 |
| 2025-12-05 | WEIN MATTHEW | General Counsel | Sale | 199 | $353 |
| 2025-12-05 | IRISH JIAN | Chief Executive Officer | Sale | 1,602 | $2,839 |
| 2025-12-05 | IRISH JIAN | Chief Executive Officer | Gift | 228,462 | - |
| 2025-12-01 | WAPNICK PAMELA M. | Chief Financial Officer | Stock Award | 120,000 | $192,000 |
| 2025-12-01 | WEIN MATTHEW | General Counsel | Stock Award | 96,000 | $153,600 |
| 2025-12-01 | IRISH JIAN | Chief Executive Officer | Stock Award | 248,500 | $397,600 |
WAPNICK PAMELA M.
Chief Financial Officer
2026-04-01
24,000 shares
WEIN MATTHEW
General Counsel
2026-04-01
11,000 shares
IRISH JIAN
Chief Executive Officer
2026-04-01
46,000 shares
WAPNICK PAMELA M.
Chief Financial Officer
2026-03-05
1,581 shares
·
$2,530
WEIN MATTHEW
General Counsel
2026-03-05
482 shares
·
$771
IRISH JIAN
Chief Executive Officer
2026-03-05
1,607 shares
·
$2,571
WAPNICK PAMELA M.
Chief Financial Officer
2025-12-05
1,576 shares
·
$2,793
THOMAS BRIAN C
Director
2025-12-05
3,830 shares
·
$6,786
WEIN MATTHEW
General Counsel
2025-12-05
199 shares
·
$353
IRISH JIAN
Chief Executive Officer
2025-12-05
1,602 shares
·
$2,839
IRISH JIAN
Chief Executive Officer
2025-12-05
228,462 shares
WAPNICK PAMELA M.
Chief Financial Officer
2025-12-01
120,000 shares
·
$192,000
WEIN MATTHEW
General Counsel
2025-12-01
96,000 shares
·
$153,600
IRISH JIAN
Chief Executive Officer
2025-12-01
248,500 shares
·
$397,600
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning MGX from our newsroom.
Newest → oldest
No matching news yet.